Showing 41 - 60 results of 193 for search '"cancer immunotherapy"', query time: 0.07s Refine Results
  1. 41
  2. 42
  3. 43

    Cyclooxygenase-2/prostaglandin E2 inhibition remodulated photodynamic therapy-associated immunosuppression for enhanced cancer immunotherapy by Tao Xu, Kehan Liu, Shuqi Mi, Yao Yao, Mengyao Zhang, Shujuan Xue, Feng Zhi, Sally-Ann Cryan, Dawei Ding

    Published 2025-04-01
    “…This study sets an intriguing example for overcoming the COX-2/PGE2 pathway-exacerbated immunosuppression alongside immune activation, thus enhancing synergistic cancer immunotherapy potentiated by various ROS-producing therapies (e.g., PDT and radiotherapy) and chemotherapy.…”
    Get full text
    Article
  4. 44
  5. 45
  6. 46
  7. 47
  8. 48

    HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders by Qin Wang, Xinyi Zhu, Jing Li, Sanjia Xu, Ali Wang, Xinwen Zhang, Xingxing Wang, Xiaopeng Cai, Haimei Xing, Ye Liu, Xuesong Liu, Zhiwei Wang, Lai Wang, Lai Wang, Xi Yuan

    Published 2025-02-01
    “…In summary, the results of this study suggested that HPK1 kinase inhibitor may be sufficient for HPK1 targeting in T cell mediated cancer immunotherapy.…”
    Get full text
    Article
  9. 49

    Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy by Xin Liu, Yang Du, Ningyan Zhang, Zhiqiang An, Wei Xiong, Yixiang Xu, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Tianhao Duan, Helen Y Wang, John S. Yu, Rongfu Wang

    Published 2022-03-01
    “…The generation of TCR-like antibody and its CAR-T cells provides the state-of-the-art platform and proof-of-concept validation to broaden the scope of target antigen recognition and sheds light on the development of novel therapeutics for cancer immunotherapy.…”
    Get full text
    Article
  10. 50

    Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy by Fermín E. González, Alexey Chernobrovkin, Cristián Pereda, Tamara García-Salum, Andrés Tittarelli, Mercedes N. López, Flavio Salazar-Onfray, Roman A. Zubarev

    Published 2018-01-01
    “…Autologous dendritic cells (DCs) loaded with cancer cell-derived lysates have become a promising tool in cancer immunotherapy. During the last decade, we demonstrated that vaccination of advanced melanoma patients with autologous tumor antigen presenting cells (TAPCells) loaded with an allogeneic heat shock- (HS-) conditioned melanoma cell-derived lysate (called TRIMEL) is able to induce an antitumor immune response associated with a prolonged patient survival. …”
    Get full text
    Article
  11. 51
  12. 52
  13. 53
  14. 54
  15. 55
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60